[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ductal-breast-carcinoma-in-situ\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ductal-breast-carcinoma-in-situ":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,95,120,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100320216","the-predict-registry-100320216",false,"NCT03448926","The PREDICT Registry:","A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy","Inclusion criteria\n\n1. Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).\n2. Patient must have the DCISionRT test ordered during routine patient care.\n3. Patient must be eligible for or have recently completed breast conserving surgery.\n4. Patient must be eligible to receive radiation and\u002For systemic treatment.\n5. Patient must be 30 to 85 years old.\n6. Patient must have tumor size of less than 6 cm.\n7. Patient must have been diagnosed with DCIS within 120 days of consent.\n\nExclusion criteria\n\n1. Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing.\n2. Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget's disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast.\n3. Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS.\n4. Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer.\n5. Patient has a prior history of in-field radiation in the ipsilateral breast.\n6. Patient has had prior systemic endocrine or chemotherapy prior to testing.\n7. Patient is pregnant.","FEMALE","30 Years","85 Years",{"count":20,"type":21},3000,"ESTIMATED","OBSERVATIONAL","This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.",[25,26,27],"DCIS","Stage 0 Breast Cancer","Ductal Breast Carcinoma In Situ",[25,29,30,31,32,33],"molecular testing","risk of recurrence","treatment decision","decision impact","predictive","RECRUITING","2026-04-14",{"date":37,"type":38},"2026-04-17","ACTUAL",{"date":40,"type":38},"2018-02-27",{"date":42,"type":21},"2036-12",{"name":44,"class":45},"PreludeDx","INDUSTRY",30,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100279522","decision-making-tool-in-supporting-decision-making-in-contralateral-prophylactic-mastectomy-in-patients-with-newly-diagnosed-breast-cancer-100279522","NCT02918474","Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer","Decision Making Tool for Contralateral Prophylactic Mastectomy","Inclusion Criteria:\n\n* Newly diagnosed ductal breast carcinoma in situ (DCIS) or stage I-III sporadic unilateral invasive breast cancer\n* Able to speak read or write English\n\nExclusion Criteria:\n\n* Patients with previous breast cancer\n* Prior history of bilateral prophylactic mastectomy\n* Known to have a germline mutation that predisposes them to an increased risk of breast cancer (e.g. BRCA1\u002F2) and\u002For they are considered at high risk for contralateral breast cancer on the basis of a strong family history of cancer","18 Years",{"count":56,"type":21},15,"INTERVENTIONAL",[59],"NA","This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer. Decision making tool may help patients with early stage breast cancer make decisions regarding their surgical options.",[62,63,64,65,66,67,68,69,70,71,27,72,73,74,75,76,77,78,79,80,81,82,83],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Sporadic Breast Carcinoma","2026-04-13",{"date":86,"type":38},"2026-04-16",{"date":88,"type":38},"2017-04-28",{"date":90,"type":21},"2026-09-30",{"name":92,"class":93},"M.D. Anderson Cancer Center","OTHER",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":57,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":94},"100355540","surgical-excision-vs-neoadjuvant-radiotherapydelayed-surgical-excision-of-ductal-carcinoma-100355540","NCT03909282","Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma","A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)","NORDIS","Inclusion Criteria\n\n* Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality\n* Signed and dated IRB-approved written informed consent\n* Women 18 years of age or older\n* Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease\n* Estrogen receptor positive or negative, progesterone receptor positive, negative or unknown; HER2 positive, negative or unknown DCIS is allowed\n* Diagnostic needle biopsy within 16 weeks of randomization\n* Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging.\n* Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible.\n* Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization\n* Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields\n* Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible\n* ECOG performance status 0, 1, or 2\n* Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed\n\nExclusion Criteria\n\n* Invasive carcinoma on core needle biopsy, including microinvasive carcinoma\n* Radiographic extent of DCIS \\>4.0 cm\n* Mass lesion on breast imaging or palpable tumor\n* No residual radiographic lesion after diagnostic percutaneous core needle biopsy\n* Prior history of ipsilateral invasive or noninvasive breast cancer\n* Pregnant or breastfeeding\n* Prior ipsilateral breast or chest irradiation\n* Multicentric or multifocal DCIS, if extent is \\> 4cm\n* Synchronous contralateral invasive or noninvasive breast cancer\n* Pagets' disease of the breast\n* Active collagen vascular disease\n* Positive axillary lymph nodes\n* Not meeting the described criteria for partial breast irradiation during initial clinical evaluation.\n* Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results\n* Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer",{"count":104,"type":21},50,[59],"The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)",[108],"Ductal Breast Carcinoma in Situ",[110],"Ductal Breast Carcinoma","2026-03-10",{"date":113,"type":38},"2026-03-12",{"date":115,"type":38},"2019-03-22",{"date":117,"type":21},"2026-12",{"name":119,"class":93},"Stanford University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":57,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":94},"100590018","phase-2-5-vs-9-day-course-of-whole-breast-radiotherapy-with-boost-for-early-stage-breast-cancer-100590018","NCT06961955","5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer","FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer","FAST NOVEMBER","Inclusion Criteria:\n\n* Female participant aged ≥ 18 years.\n\n  --Participants must have at least one of the following risk factors:\n  * Grade 3 invasive histology\n  * Estrogen receptor positivity less than 5%\n  * Lymphovascular invasion\n  * Invasive margins \\\u003C2mm on surgical pathology\n  * DCIS final positive margin\n  * Extensive intraductal component\n  * Age ≤ 50 years\n  * Tumor size \\> 2 cm\n* Histologically confirmed invasive carcinoma or Ductal Carcinoma In Situ (DCIS) of the breast.\n* Breast cancer stage (AJCC v8) T0-3, N0, M0. T0 N0 is allowed if whole breast radiation is recommended by the treating physician.\n* Lumpectomy within 84 days of the start of radiation.\n* ECOG Performance Status ≤ 2, or KPS ≥ 50\n* Negative inked histologic margins from lumpectomy, with the exception of a focus of positive margin at the pectoralis fascia.\n* Negative pregnancy test for participants of childbearing potential, evidence of permanent surgical sterilization, or post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Sexually active participants of childbearing potential must agree to use highly effective method of contraception (defined in Section 5.4.1) during the course of radiation and for 30 days after radiation.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Bilateral breast cancer.\n* Prior radiation therapy to the chest.\n* Prior chemotherapy.\n* Recurrent disease.\n* Known metastases or node positive.\n* Major chest surgery which is expected to impact study participation 8 weeks prior to starting study drug.\n* Prior breast malignancy in either breast.\n* The diagnosis of any other malignancy which, in the opinion of the Investigator, is likely to negatively impact the subject's safety or ability to participate in the study.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow, social\u002F psychological issues, etc.)\n* Significant post lumpectomy complications requiring an unplanned re-operation for surgical complications or admission for IV antibiotics. Re-operation for margins evaluation or nodal evaluation is acceptable. Draining of a seroma is not considered a complication unless it has become infected.\n* Breast neuroendocrine carcinoma or sarcoma histology.\n* Radiation sensitizing disease or condition (e.g. connective tissue disease, li fremani, etc.).\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Participants receiving concurrent radiation sensitizing medications or therapies.",{"count":129,"type":21},144,[131],"PHASE2","The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.",[134,135,108],"Breast Cancer","Invasive Carcinoma of Breast","2025-12-02",{"date":138,"type":38},"2025-12-09",{"date":140,"type":38},"2025-05-21",{"date":142,"type":21},"2033-05",{"name":144,"class":93},"University of Utah",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100591732","hypofractionated-radiotherapy-with-concomitant-tumor-bed-boost-for-breast-cancer-100591732","NCT06984250","Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer","Hybrid Techniques Combining Hypofractionated Whole Breast Radiotherapy With Concomitant Tumor Bed Boost in Patients With Breast Cancer","HFCBB","Inclusion Criteria:\n\n* Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).\n* Patients undergoing breast-conserving surgery\n* Age ≥ 20 years\n* Karnofsky Performance Status (KPS) ≥70%\n* Life expectancy ≥ 5 years\n* Adequate renal and hepatic function\n\nExclusion Criteria:\n\n* Pregnant patients\n* Patients requiring re-irradiation of the thoracic region","20 Years",{"count":155,"type":21},315,"Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy",[158,27],"Early Breast Cancer",[160,161,162,163,164],"breast cancer","concomitant boost","tumor bed","Intensity-modulated radiation therapy","hypofractionated breast radiotherapy","2025-05-19",{"date":167,"type":38},"2025-05-22",{"date":169,"type":38},"2025-02-06",{"date":171,"type":21},"2030-02-28",{"name":173,"class":93},"National Taiwan University Hospital",2]